Ghosh Hia S, Patel Ruchit V, Claus Elizabeth B, Gonzalez Castro Luis Nicolas, Wen Patrick Y, Ligon Keith L, Meredith David M, Bi Wenya Linda
Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Neuro Oncol. 2025 May 15;27(4):993-1003. doi: 10.1093/neuonc/noae258.
Molecular features have been incorporated alongside histologic criteria to improve glioma diagnostics and prognostication. CDKN2A/B homozygous-loss associates with worse survival in IDH1/2-mutant astrocytomas (IDHmut-astrocytomas), the presence of which denotes a grade 4 tumor independent of histologic features. However, no molecular features distinguish survival amongst histologically defined grade 2 and 3 IDHmut-astrocytomas.
We assembled a cohort of patients ≥19 years old diagnosed with an IDHmut-astrocytoma between 1989 and 2020 from public datasets and several academic medical centers. Multivariate modeling and unbiased clustering were used to stratify risk.
We identified 998 IDHmut-astrocytoma patients (41.5% female; 85.6% white). Tumor grade, CDKN2A/B loss, and/or ≥1 focal amplification were associated with reduced survival. Grade 2/3 patients with intact CDKN2A/B and no focal amplifications survived the longest (OS 205.7 months). Survival for grade 2/3 cases with either CDKN2A/B hemizygous-loss or focal amplifications (80.4, 88.7 months respectively) did not differ significantly from grade 4 cases with intact CDKN2A/B and no amplifications (91.5 months, P = .93). Grade 4 patients with either hemizygous or homozygous loss of CDKN2A/B had the shortest survival (OS 31.9, 32.5 months respectively), followed by grade 4 cases with intact CDKN2A/B and focal gene amplifications (OS 55.9 months). Integrating CDKN2A/B status and amplifications alongside histopathologic grade refined overall survival prediction. Unbiased clustering revealed 9 distinct molecular profiles, with differential survival. IDHmut-astrocytomas with any CDKN2A/B loss clustered together, regardless of grade, and exhibited the poorest outcomes.
Combining CDKN2A/B hemizygous-loss and focal gene amplifications reveals a group of IDHmut-astrocytoma patients with an intermediate prognosis, refining IDHmut-astrocytoma classification.
分子特征已与组织学标准相结合,以改善胶质瘤的诊断和预后评估。CDKN2A/B纯合缺失与异柠檬酸脱氢酶1/2突变型星形细胞瘤(IDH突变型星形细胞瘤)的较差生存率相关,其存在表明肿瘤为4级,与组织学特征无关。然而,在组织学定义的2级和3级IDH突变型星形细胞瘤中,没有分子特征能够区分生存率。
我们从公共数据集和几个学术医疗中心收集了一组1989年至2020年间诊断为IDH突变型星形细胞瘤的19岁及以上患者。采用多变量建模和无监督聚类进行风险分层。
我们确定了998例IDH突变型星形细胞瘤患者(41.5%为女性;85.6%为白人)。肿瘤分级、CDKN2A/B缺失和/或≥1个局灶性扩增与生存率降低相关。CDKN2A/B完整且无局灶性扩增的2/3级患者生存期最长(总生存期205.7个月)。CDKN2A/B半合子缺失或局灶性扩增的2/3级病例(分别为80.4、88.7个月)与CDKN2A/B完整且无扩增的4级病例(91.5个月,P = 0.93)的生存率无显著差异。CDKN2A/B半合子或纯合子缺失的4级患者生存期最短(总生存期分别为31.9、32.5个月),其次是CDKN2A/B完整且有局灶性基因扩增的4级病例(总生存期55.9个月)。将CDKN2A/B状态和扩增与组织病理学分级相结合可改善总生存期预测。无监督聚类揭示了9种不同的分子谱,生存率存在差异。任何CDKN2A/B缺失的IDH突变型星形细胞瘤聚集在一起,无论分级如何,预后最差。
结合CDKN2A/B半合子缺失和局灶性基因扩增可发现一组预后中等的IDH突变型星形细胞瘤患者,完善了IDH突变型星形细胞瘤的分类。